Dr. Elizabeth Mittendorf on Clinical Trials Exploring a New Breast Cancer Vaccine
Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses an upcoming peptide vaccine to prevent recurrence in patients with breast cancer.
Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses an upcoming peptide vaccine to prevent recurrence in patients with breast cancer. Mittendorf says initially there was the HER2 peptide nelipepimut-S (E75) vaccine (NeuVax) that proved to be immunogenic. She says in a recent study, her and her colleagues combined E75 with GMCSF to help prevent recurrence.
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
Navigating HER2+ Early Breast Cancer: Insights Into the Current Treatment Landscape
November 28th 2023In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer
November 22nd 2023In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.
Read More
